sIPV + DTaP + HepA-L

sIPV + DTaP + HepA-L is a combination vaccine formulation that, by its name, would contain the following components: - sIPV (Sabin strain Inactivated Poliovirus Vaccine): provides immunity against poliovirus. - DTaP (Diphtheria, Tetanus, and Acellular Pertussis): protects against diphtheria, tetanus (lockjaw), and pertussis (whooping cough). - HepA-L (Hepatitis A vaccine - likely "Live" or "Low-dose", but this abbreviation is not standard in current US/EU practice; most hepatitis A vaccines are inactivated). Combination vaccines are designed to reduce the number of injections required for immunization while providing protection against multiple diseases. Each component works by stimulating the immune system to produce antibodies specific to each pathogen. The mechanism of action for each antigen involves induction of adaptive immunity—primarily humoral responses—against their respective pathogens. As of June 2025, there is no evidence from major regulatory agencies or immunization schedules that a licensed combination vaccine containing all three components—sIPV, DTaP, and hepatitis A—is available or approved in the United States or other major markets[1][4][5]. Existing combination vaccines typically include combinations such as DTaP-IPV-HepB (e.g., Pediarix), DTaP-IPV-Hib-HepB (e.g., Vaxelis), but not hepatitis A[1][4][5]. Current recommendations require hepatitis A vaccination as a separate injection when using these combinations[5].

Other names

Sabin-strain Inactivated Polio Vaccine + Diphtheria, Tetanus, and acellular Pertussis Vaccine + Live Attenuated Hepatitis A VaccineCombined immunization of sIPV, DTaP and HepAsIPV+DTaP+HepA